Client News

OKYO Pharma Limited: Conversion of CLNs, cashless exercise of Warrants, and issue of equity
Home / Client News / OKYO Pharma Limited: Conversion of CLNs, cashless exercise of Warrants, and issue of equity

21 February 2022 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has today issued 403,719,360 new ordinary shares of no par value (“Ordinary Shares”), credited as fully paid on conversion of all outstanding convertible loan notes (“Conversion”) and the cashless exercise of all outstanding warrants, including those resulting from the Conversion.

https://www.londonstockexchange.com/news-article/OKYO/cln-conversion-exercise-of-warrants-equity-issue/15337243

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This